glp 1 companion semaglutide support A new study conducted by leading researchers across the United States suggests GLP-1s could have a much greater impact beyond obesity. Follow the link in our bio for more on the study Noom: Lose weight and keep

Studies typically include untreated controls and vehicle controls

Aaron Hartman, MD is board certified in Functional Medicine, Integrative & Holistic Medicine, Family Medicine, as well as Anti-Aging & Regenerative Medicine

Real Progress Bite-sized, daily lessons Human coaching with AI-powered support Personalized tools built around you And so much more The Foundation Behind Every Noom Prescription Nooms science-backed program helps people build healthier habits so results last beyond medication

The efficacy of GIP/GLP1 receptor co-agonists on glucose control is surprising, and allows to reach glucose levels similar to diabetes remission in a greater percentage of patients compared to other treatments

Dreisler E, Kjer JJ